Patents Represented by Attorney Lawrence Gilbert
  • Patent number: 5155209
    Abstract: The R-(+) enantiomeric form of .+-. racemic 7-(2, 3-empoxypropoxy) actinomycin D (EPA) is provided which is effective in the therapeutic treatment of cancer. The analogue has the formula: ##STR1## wherein the P's are: ##STR2## The enantiomeric form is uniformly superior to other forms of the compound in treating malignant tumors.
    Type: Grant
    Filed: August 19, 1991
    Date of Patent: October 13, 1992
    Assignee: Trustees of Boston University
    Inventor: Sisir Sengupta
  • Patent number: 4946774
    Abstract: A process for detecting cancer in a human patient is provided wherein a blood serum is recovered from the patient and is reacted with a monoclonal antibody comprising anti-haptoglobin variant under conditions to effect an immunoreaction when an immunosuppressive factor having a molecular weight of about 50K Daltons is present in the serum. The presence of immunosuppressive factor at concentration levels substantially exceeding normal concentration levels indicates the existence of immunoincompetence due to widely spread cancer. The effectiveness of cancer therapy is monitored by monitoring the change in levels of the immunosuppressive haptoglobin variant factor in the serum from the patient being treated.
    Type: Grant
    Filed: November 9, 1987
    Date of Patent: August 7, 1990
    Assignee: Trustees of Boston University
    Inventor: Se-Kyung Oh
  • Patent number: 4576948
    Abstract: New uracil compounds having the formula: ##STR1## wherein X is C.sub.1 -C.sub.10 alkoxy or amino are provided. These compounds are useful in treating patients having leukemia, the cells of which express terminal deoxynucleootidyl transferase.
    Type: Grant
    Filed: January 20, 1983
    Date of Patent: March 18, 1986
    Assignee: Trustees Boston University
    Inventors: Ronald McCaffrey, George Wright, Earl F. Baril
  • Patent number: 4537712
    Abstract: A high purity immunosuppression factor (IF) having a molecular weight of about 50,000 or a reduced IF having a molecular weight of about 25,000 derived from the higher molecular weight IF and which is stable in dilute aqueous solutions is obtained from human ascites fluid. An extract of human ascites fluid is subjected to chromatography to recover a component of the ascites fluid rich in the immunosuppression factor and containing proteinaceous material which does not degrade the IF factor. The pure IF is obtained by subjecting the component rich in IF to contact with solid phase anti-human IgG (Fc specific) to recover pure IF having a molecular weight of above 50,000. The reduced IF is obtained by heating the higher molecular weight IF.
    Type: Grant
    Filed: September 19, 1983
    Date of Patent: August 27, 1985
    Assignee: Trustees of Boston University
    Inventor: Se-Kyung Oh
  • Patent number: 4514330
    Abstract: 7-(2,3-Epoxypropoxy)actinomycin D has been synthesized along with its major companion product, 7-(2,3-dihydroxypropoxy)-actinomycin D. They were characterized by UV-visible and CD spectra and by NMR studies. According to UV-visible absorptiometry, circular dichroism, and thermal denaturation studies, they bind to DNA in a manner that is comparable to actinomycin D. The analogues are, like actinomycin D, extremely cytotoxic to human lymphoblastic leukemic cells (CCRF-CEM) in vitro but are significantly less toxic than actinomycin D to normal CDF.sub.1 mice in vivo. Unlike actinomycin, these analogues are metabolized in rats, and the metabolites are excreted in rat urine at a rapid rate. Compared to actinomycin D, the antitumor activity of the 7-(2,3-epoxypropoxy)actinomycin analogue against P-388 leukemia in mice is decidedly superior, and the therapeutic index is improved several fold.
    Type: Grant
    Filed: June 28, 1983
    Date of Patent: April 30, 1985
    Assignee: Trustees of Boston University
    Inventor: Sisir K. Sengupta
  • Patent number: 4500524
    Abstract: Seizures are inhibited or prevented and tranquilizing effect induced by administering riboflavin or a riboflavin analog, alone or in combination with a conventional anticonvulsant or tranquilizer to enhance its effect.
    Type: Grant
    Filed: August 11, 1983
    Date of Patent: February 19, 1985
    Assignee: Trustees of Boston University
    Inventor: Nicholas Catsimpoolas
  • Patent number: 4479930
    Abstract: A dicyclic dianhydride rapidly and efficiently couples with a broad variety of amines such as polypeptides and proteins in non-aqueous or aqueous media and then may be chelated with a wide choice of radioisotope metallic cations to yield a radio-labeled product that is stable in vivo. A simple 1-step synthesis of the coupled amine in aqueous solution of neutral pH is described which requires only a few minutes time and with little accompanying hydrolysis.
    Type: Grant
    Filed: July 26, 1982
    Date of Patent: October 30, 1984
    Assignee: Trustees of the University of Massachusetts
    Inventor: Donald J. Hnatowich
  • Patent number: 4403939
    Abstract: Apparatus for forming a film of uniformly oriented molecules from a solution or suspension of the molecules including means to house the molecules in a swinging bucket centrifugation apparatus. The housing means has a gravitational isopotential surface with a radius of curvature equal to the distance between the surface and the spin axis of the centrifugation apparatus. The isopotential surface is normal to the direction of the gravitational forces during spinning. Means for evaporating solvent during centrifugation is provided.
    Type: Grant
    Filed: September 16, 1980
    Date of Patent: September 13, 1983
    Assignee: Trustees Boston University
    Inventors: Kenneth J. Rothschild, Noel A. Clark